Actavis has launched Potactasol 4mg powder for concentrate for solution for infusion (topotecan). Topotecan monotherapy is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy and patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.

It can be used in combination with cisplatin for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease.

Please refer to the link below for the New SPC for new product Potactasol powder for concentrate for solution for infusion.